ArticleBMC research notes2020
Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy.
Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Exploring the psychodermatologic burden and associated psychiatric manifestations in rosacea: a systemic review.Archives of dermatological research · 2025Pooled it
- Association of peripheral manifestation of brain-derived neurotrophic factor with depression: A meta-analysis.Brain and behavior · 2022Pooled it
- Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis.International journal of immunopathology and pharmacologyPooled it
- Trial
- A history of maternal separation drives systemic aging-associated signatures in middle-aged male rats.Frontiers in cellular neuroscience · 2026Article
- Towards Objective Major Depressive Disorder Detection: a Systematic Review and Meta-Analysis of Diagnostic Biomarkers.The Psychiatric quarterly · 2025Review
- Risk factors, protective factors, peripheral biomarkers, and neurocognitive markers associated with mood disorders: An umbrella review of 103 meta-analyses and systematic reviews.Brain, behavior, & immunity - health · 2025Review
- Article
- Evaluation of serum brain-derived neurotrophic factor, IL-6, IL-10, and TNF-a cognitive function, and sleep quality in elderly patients with major depressive disorder and somatic symptoms.Journal of medical biochemistry · 2025Article
- Emerging and accumulating safety signals for the use of estrogen among transgender women.Discover mental health · 2025Review
- Remodeling the Epigenome Through Meditation: Effects on Brain, Body, and Well-being.Sub-cellular biochemistry · 2025Review
- Filbertone-Induced Nrf2 Activation Ameliorates Neuronal Damage via Increasing BDNF Expression.Neurochemical research · 2024Article
- Increased serum EGF but not SDF-1 levels are associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- An Observational Case-control Study for BDNF Val66Met Polymorphism and Serum BDNF in Patients with Major Depressive Disorder (MDD).Indian journal of psychological medicine · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design.BMC psychiatry · 2024Article
- Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression.Frontiers in neurology · 2024Article
- Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.PloS one · 2024Article
- Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study.BMC psychiatry · 2023Article
- Serum concentrations of BDNF in adolescents with metabolic syndrome: a case-control study between normal - BMI adolescents and adolescents with obesity.European journal of pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe do not have any consistent markers for major depressive disorder (MDD) though various biological factors are involved in the pathophysiology. We aimed to evaluate the serum brain-derived neurotrophic factor (BDNF) levels in MDD patients with or without antidepressant therapy compared to healthy controls (HCs).
resultsWe assessed serum BDNF levels among three groups: drug-naïve MDD patients (n = 41), drug-treated MDD patients (n = 44), and age-and sex-matched HCs (n = 82). Serum BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. Serum levels of BDNF were detected significantly lower in drug-naïve MDD patients compared to HCs. No significant alterations of serum BDNF levels between drug-treated patients and HCs were identified. Significant negative correlations between serum BDNF levels and Hamilton depression rating (Ham-D) scores were observed in both drug-naïve and drug-treated MDD patients. Receiver operating characteristic (ROC) analysis showed good diagnostic value for serum BDNF levels in drug-naïve MDD patients with the area under the curve at 0.821. The present study suggests that low serum BDNF levels may be involved in the pathophysiology of MDD. The reduced serum BDNF levels might be used as an early risk assessment marker for major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.